活动后气短、上楼乏力、长期疲惫、食欲减退……这些"小毛病"常被简单归结为老了、累了，但也可能 是心力衰竭（简称"心衰"）的重要信号。随着人口老龄化加剧和心血管疾病谱变化，心衰已成为我国公 共卫生的重要挑战。北京医院杨杰孚、王华团队近期在《欧洲心脏杂志》发表的研究预测，到2035年， 我国心衰患者数量将增长至2270万，较2021年增加超七成。 心衰是冠心病、高血压等心血管疾病发展的严重或终末阶段，此时心脏泵血功能衰退，再也无法有力地 将血液输送到全身，进而引起缺氧和瘀血。其典型表现包括呼吸困难、乏力、下肢水肿等，严重时可能 危及生命。 上述研究中，研究者基于2021年全球疾病负担研究、中国心血管健康联盟注册数据库和国家医保数据， 预测了2025~2035年心衰负担及其对经济发展的影响。研究预计，从2021年至2035年，我国心衰患者总 数将由1310万激增至2270万，增幅高达73%，在此期间，年龄标准化患病率从693.5例/10万人攀升至 760.7例/10万人。其中，60岁以上人群患病率增长最快，35~39岁年轻患者比例也有明显上升。 研究还提到，2025~2035年，心衰导致的累计经济损失预计超过1万亿 ...

Core Viewpoint - The incidence of coronary heart disease is trending younger, with an increasing number of young and middle-aged individuals suffering from hypertension, diabetes, and hyperlipidemia, leading to cases of myocardial infarction and heart failure [1] Group 1: Risk Factors - Atherosclerosis is a major cause of cardiovascular diseases, which can develop over many years. Common risk factors include hypertension, diabetes, hyperlipidemia, poor diet, lack of exercise, and obesity [1] - Young individuals may already have significant plaque buildup in their blood vessels due to these risk factors, highlighting the need for early intervention [1] Group 2: Warning Signs - Common warning signs of cardiovascular issues include discomfort in the chest area, which may manifest as tightness or burning sensations, especially during physical activity, emotional stress, or after meals [2] - Symptoms may radiate to the jaw, shoulders, arms, back, and upper abdomen, indicating potential myocardial ischemia [2] - Additional symptoms may include gastrointestinal issues such as nausea and vomiting, often accompanied by palpitations, shortness of breath, dizziness, and extreme fatigue, which could signal acute myocardial infarction [2] Group 3: Medical Attention and Monitoring - If symptoms occur frequently or worsen, immediate medical attention is advised [3] - Regular health check-ups are recommended to monitor blood pressure, blood sugar, blood lipids, and ECG results, with prompt medical intervention for any abnormalities [4]

Core Insights - The article discusses the current state and future prospects of the long-term circulatory support industry, emphasizing its significance in treating end-stage heart failure patients and the expected growth in patient numbers and market size. Group 1: Industry Overview - The long-term circulatory support industry provides essential services for patients with end-stage heart failure, utilizing devices such as implantable ventricular assist devices and total artificial hearts [4][5]. - The industry is characterized by a high complexity and heterogeneity, with various classification systems for heart failure, including NYHA and INTERMACS [5][6]. Group 2: Epidemiology and Patient Demographics - In China, approximately 65% of heart failure patients are in the early stage, 25% in the progressive stage, and 10% in the end-stage [7]. - The annual incidence of heart failure in China is reported to be 275 per 100,000 people, with a standardized prevalence of 1.10% among adults aged 25 and older [7][8]. Group 3: Global Market Trends - The global heart failure patient population is projected to grow from 62.98 million in 2024 to 71.51 million by 2033, with a compound annual growth rate (CAGR) of 1.4% [10]. - In China, the number of heart failure patients is expected to increase from 15.35 million in 2024 to 17.72 million by 2033, with a CAGR of 1.6% [10]. Group 4: Clinical Application and Challenges - End-stage heart failure has a poor prognosis, with a one-year mortality rate close to 50%, and a median time from diagnosis to death of approximately 12.2 months [6][10]. - The article highlights the need for improved treatment options and the role of long-term circulatory support devices in enhancing patient outcomes [4][5].

Core Insights - The research indicates that fibroblasts, previously thought to only support myocardial cells structurally, play a significant role in the deterioration of heart failure [1][2] - The study highlights the activation of specific fibroblast populations during heart failure, with the transcription factor c-MYC being notably expressed [1] - The findings suggest a potential new therapeutic strategy targeting non-myocardial cells in heart failure treatment, moving beyond the traditional focus on damaged myocardial cells [2] Group 1: Research Findings - Heart failure is a severe condition characterized by decreased cardiac pumping function, leading to symptoms such as dyspnea, edema, and fatigue, with a high mortality rate [1] - The research team published their findings in the journal "Nature - Cardiovascular Research," demonstrating that c-MYC induces the secretion of chemokine CXCL1, which negatively impacts myocardial cell contraction [1] - Inhibition of c-MYC expression in experimental mice resulted in improved cardiac function and increased survival rates, while forced expression of c-MYC led to significant cardiac decline [1] Group 2: Implications for Treatment - The study analyzed cardiac tissues from heart failure patients, corroborating the findings from experimental mice, indicating potential applicability to human heart failure cases [2] - The research marks a significant step towards establishing new treatment strategies that target non-myocardial cells, addressing the limited treatment options currently available for severe heart failure [2]

Group 1 - High temperatures, high humidity, and low pressure are significant contributors to cardiovascular diseases, with an increase in heart attack patients reported in Hangzhou [1] - The director of the cardiology department at Zhejiang University Second Hospital noted that over 20 heart attack patients have been treated in the past month due to the heat [1] - Factors such as skin blood vessel dilation, increased blood viscosity, and emotional stress during hot weather can elevate the risk of heart attacks [1] Group 2 - Patients with hypertension, diabetes, and hyperlipidemia are advised to monitor their blood pressure daily and adhere strictly to medication regimens [2] - Recommendations include drinking warm water in small amounts, avoiding cold drinks, and exercising during cooler times of the day [2] - Immediate medical attention is crucial if symptoms like chest pain, shortness of breath, or dizziness occur, as these may indicate serious conditions like heart failure or stroke [2]

Core Viewpoint - The study indicates that optogenetic vagal nerve stimulation (VNS) can alleviate heart failure (HF) by limiting the generation of monocyte-derived inflammatory CCRL2+ macrophages [2][3][4]. Summary by Sections Mechanism of Action - The research demonstrates that VNS reduces the proportion of CCRL2+ macrophages, which are derived from myeloid monocytes and exhibit unique tumor necrosis factor alpha (TNF-α) cytokine responses, hypertrophic, and fibrotic characteristics [4]. - The elimination of CCRL2+ macrophages can prevent cardiac remodeling and heart failure [4]. Key Findings - The study confirms a positive correlation between CCRL2+ macrophages and TNF-α responsive proteins in the human heart with cardiac remodeling and dysfunction [5]. - Activation of the α7 nicotinic acetylcholine receptor (α7nAChR) plays a crucial role in the cardiac protective effects mediated by VNS, as it inhibits the response of CCRL2+ macrophages to TNF-α by increasing the expression of the transcription factor NRF2 [4][5]. Therapeutic Implications - Overall, the results suggest that the vagus nerve-immune axis can regulate heart failure and represents a promising therapeutic target [6].